Zacks: Brokerages Expect GW Pharmaceuticals PLC- (NASDAQ:GWPH) to Announce -$0.66 Earnings Per Share

Analysts expect GW Pharmaceuticals PLC- (NASDAQ:GWPH) to post earnings of ($0.66) per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for GW Pharmaceuticals PLC-‘s earnings, with estimates ranging from ($1.56) to ($0.36). GW Pharmaceuticals PLC- posted earnings per share of ($2.35) during the same quarter last year, which indicates a positive year over year growth rate of 71.9%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, February 25th.

According to Zacks, analysts expect that GW Pharmaceuticals PLC- will report full-year earnings of ($0.15) per share for the current fiscal year, with EPS estimates ranging from ($1.08) to $0.24. For the next fiscal year, analysts forecast that the business will post earnings of $1.68 per share, with EPS estimates ranging from ($0.60) to $9.00. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that cover GW Pharmaceuticals PLC-.

Several equities research analysts have commented on GWPH shares. Zacks Investment Research cut shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Bank of America restated a “buy” rating and set a $218.00 price objective on shares of GW Pharmaceuticals PLC- in a research report on Wednesday, September 25th. Evercore ISI reaffirmed a “buy” rating on shares of GW Pharmaceuticals PLC- in a research note on Monday, November 11th. Needham & Company LLC assumed coverage on shares of GW Pharmaceuticals PLC- in a report on Monday, October 21st. They issued a “buy” rating and a $200.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $174.00 target price on shares of GW Pharmaceuticals PLC- in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have issued a buy rating to the company’s stock. GW Pharmaceuticals PLC- presently has a consensus rating of “Buy” and an average price target of $199.18.

GWPH stock traded up $6.36 during trading hours on Thursday, hitting $102.46. 1,001,773 shares of the stock traded hands, compared to its average volume of 538,041. The stock has a 50-day simple moving average of $113.61 and a 200 day simple moving average of $143.69. The company has a market cap of $2.97 billion, a P/E ratio of -9.70 and a beta of 2.17. GW Pharmaceuticals PLC- has a one year low of $90.14 and a one year high of $196.00. The company has a current ratio of 7.33, a quick ratio of 6.60 and a debt-to-equity ratio of 0.03.

In other news, Chairman Geoffrey W. Dr Guy sold 420,000 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $108.41, for a total transaction of $45,532,200.00. Corporate insiders own 3.60% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Kavar Capital Partners LLC purchased a new stake in GW Pharmaceuticals PLC- during the second quarter valued at about $26,000. Prestige Wealth Management Group LLC purchased a new position in shares of GW Pharmaceuticals PLC- in the second quarter worth approximately $28,000. Pathstone Family Office LLC acquired a new stake in shares of GW Pharmaceuticals PLC- during the second quarter valued at approximately $29,000. Redhawk Wealth Advisors Inc. acquired a new stake in shares of GW Pharmaceuticals PLC- during the second quarter valued at approximately $34,000. Finally, Signaturefd LLC raised its holdings in shares of GW Pharmaceuticals PLC- by 192.5% during the third quarter. Signaturefd LLC now owns 234 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 154 shares during the period. 81.12% of the stock is currently owned by hedge funds and other institutional investors.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Featured Article: Understanding Relative Strength Index

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.